Verified American Company Independently reviewed and approved · June 2026

ABBOTT LABORATORIES

$90.50 -0.63% NYSE: ABT · 15-min delayed

ABBOTT PARK, Illinois
Public · NYSE: ABT
115,000 employees
Founded 1888

Visit website Follow

$158.6BMarket cap

$44.3BRevenue · FY2025

$6.5BNet income

115,000Employees

ABTNYSE

1949IPO

About ABBOTT LABORATORIES

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

American Credentials

Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →

Company facts

Founded: 1888
Type: Public · NYSE: ABT
Employees: 115,000
IPO date: Apr 19, 1949
Headquarters: 100 ABBOTT PARK ROAD
ABBOTT PARK, Illinois 60064-3500
Phone: (224) 667-6100
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: ABT NYSE
SEC CIK: 1800
LEI: 549300I73MX1K4BJJV80
EIN: 360698440
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow ABBOTT LABORATORIES and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $44.3B
Net income: $6.5B
Total assets: $86.7B
Market cap: $158.6B
Gross margin: 56.4%
Operating margin: 18.2%
Net margin: 14.7%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $44.3B
Cost of revenue: $19.3B
Gross profit: $25.0B
Operating expenses: $17.0B
Operating income: $8.1B
Income tax: $1.9B
Net income: $6.5B
EPS (basic): $3.73
EPS (diluted): $3.72

Balance sheet

Total assets: $86.7B
Current assets: $26.0B
Total liabilities: $33.9B
Current liabilities: $16.5B
Shareholders’ equity: $52.8B

Cash flow

Operating cash flow: $9.6B
Investing cash flow: -$2.4B
Financing cash flow: -$6.3B
Net cash flow: $835.0M

Statements via Polygon.io (SEC filings)

NYSE: ABT

$90.50 -0.63%

15-minute delayed · data by Polygon.io

Past year

$82.56 $138.08

52-week range

Market cap: $158.6B
P/E ratio: 24.3
EPS (diluted): $3.72
Dividend yield: 2.78%
Shares outstanding: 1.8B
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Apr 19, 1949

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Profitable — net income of $6.5B in FY2025.
Revenue grew 3% from FY2021 to FY2025.
Gross margin of 56.4%, net margin 14.7%.
Trading 34% below its 52-week high.
Pays a dividend yielding about 2.78% annually.
Valued at a price-to-earnings (P/E) ratio of 24.3.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.